Evidence map›Paper›PMID 34534513›Full record

ArticleThe Lancet. Infectious diseases2022

Remdesivir, on the road to DisCoVeRy.

Iwein Gyselinck, Wim Janssens

Abstract readComment
In one paragraph

Article in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022
    Article
  2. Article
  3. Article
  4. Assessing the evidence on remdesivir.The Lancet. Infectious diseases · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Iwein GyselinckRespiratory Diseases, University Hospitals Leuven, BREATHE Research Group, Department CHROMETA, KU Leuven, 3000 Leuven, Belgium. Electronic address: iwein.gyselinck@kuleuven.be.
Wim JanssensRespiratory Diseases, University Hospitals Leuven, BREATHE Research Group, Department CHROMETA, KU Leuven, 3000 Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlanineAdenosine MonophosphateHumansAdenosine MonophosphateAlanineremdesivir

Identifiers

PMID34534513
PMCPMC8439616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.